Uniquest Pty Ltd. has synthesized tyrosine-protein kinase SYK inhibitors reported to be useful for the treatment of allergy, cancer, fungal infections, rheumatoid arthritis, osteoporosis, liver, lung and periodontal diseases, among others.
The National Institute of Allergy and Infectious Diseases (NIAID) is set to conduct a phase I trial with Tonix Pharmaceuticals Holding Corp.’s TNX-1800 (recombinant horsepox virus, live vaccine), a vaccine candidate to protect against COVID-19.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have launched a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly hemorrhagic fevers with epidemic and pandemic potential.
Antibiotic resistance represents a global threat that leads to high morbidity and mortality. There is an urgent need for new strategies to combat persistent and resistant bacteria.
Access Vascular Inc. (AVI) closed a $22 million series C funding round that it plans to use principally to increase production capacity for its Mimix hydrophilic biomaterial vascular access devices. The company’s catheters are designed to evade identification as foreign bodies, reduce bacterial adhesion and eliminate catheter-related thrombus development.
At the IDWeek 2023 infectious disease conference, Rachelle Koch, a medical student from the University of Texas Southwestern Medical Center, presented the work done in David Greenberg’s Lab on a new strategy to tackle Pseudomonas aeruginosa infections using D-peptide-conjugated phosphorodiamidate morpholino oligomers (D-PPMOs). P. aeruginosa is an opportunistic pathogen showing a multidrug-resistance (MDR) pattern that is at the root of significant morbidity and mortality, especially in immunocompromised patients with severe chronic lung diseases such as cystic fibrosis.
RSS
